Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal ArticleDOI
Oral immunotherapy combined with omalizumab for high-risk cow's milk allergy: a randomized controlled trial.
Masaya Takahashi,Kazuhiko Soejima,Shoichiro Taniuchi,Yasuko Hatano,Sohsaku Yamanouchi,Hideki Ishikawa,Makoto Irahara,Youhei Sasaki,Hiroshi Kido,Kazunari Kaneko +9 more
TL;DR: OIT combined with OMB using microwave heated CM may help to induce desensitization for children with high-risk CM allergy, according to a prospective randomized controlled trial that was prematurely discontinued due to overwhelming superiority of OMB combined with microwave heated OIT over CM avoidance.
Journal ArticleDOI
Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study.
Aikaterini Detoraki,Lorena Di Capua,Gilda Varricchi,Arturo Genovese,Gianni Marone,Giuseppe Spadaro +5 more
TL;DR: In patients with EGPA and moderate to severe allergic asthma, omalizumab can be beneficial and safe and enables corticosteroid tapering while decreasing eosinophilia and improving asthma symptoms over 36 months.
Journal ArticleDOI
Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma.
TL;DR: HMabs targeting IL‐5 have shown great promise in severe refractory asthma with a persisting eosinophilia, and clinical trials with hMabs against IL‐13 and IL4Rα have also shown clinical benefit.
Journal ArticleDOI
Biologic targeted therapy in allergic asthma
TL;DR: The introduction of each new biologic therapy into clinical trials has been associated with great anticipation, but the outcome of these trials, in many cases, has led to disappointment and emphasized that asthma is a complex clinical syndrome with multiple underlying genotypes and clinical phenotypes.
Journal ArticleDOI
Asthma Phenotypes and Interleukin-13 — Moving Closer to Personalized Medicine
TL;DR: A large clinical trial of patients with moderate asthma found one of three patients had asthma that was not well controlled despite the regular use for 1 year of fluticasone, an inhaled glucocorticoid, and salmeterol, a long-acting beta-agonist.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.